Capivasertib (** Generic (investigational) **)

Other Medications

EU Experimental ES Not available 2 Clinical Trials

Description

Capivasertib is under investigation for the treatment of metastatic colorectal cancer (mCRC) in combination with other agents, particularly in patients with PIK3CA-mutant tumors; it has shown promising activity in early-phase clinical trials and is currently being evaluated in phase III studies to confirm its efficacy and safety.

Mechanism of Action

Capivasertib is a potent and selective inhibitor of AKT kinases, which are key mediators downstream of PI3K signaling pathway; it blocks the phosphorylation of AKT substrates, thereby inhibiting cell proliferation and survival.

Side Effects

Diarrhea; fatigue; nausea; vomiting; hyperglycemia; neutropenia; anemia; thrombocytopenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07287917 Phase 1
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
United States
NCT02465060 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
United States, Guam, Puerto Rico

Quick Info

Brand Name** Generic (investigational) **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.